(Circulation. 2000;101:1091.)
© 2000 American Heart Association, Inc.
Clinical Investigation and Reports |
From the A.I. Virtanen Institute (J.L., P.L., S.Y.-H.) and Department of Medicine, University of Kuopio (S.Y.-H.), Kuopio, Finland; and the Sir William Dunn School of Pathology, University of Oxford, Oxford, UK (P.J.G., D.R.G., S.G.).
Correspondence to Seppo Ylä-Herttuala, MD, PhD, A.I. Virtanen Institute, University of Kuopio, PO Box 1627, FIN-70211 Kuopio, Finland. E-mail seppo.ylaherttuala{at}uku.fi
BackgroundMacrophage scavenger receptors (MSRs) play an important role in the pathogenesis of atherosclerosis. Therefore, local modulation of MSR activity could have a beneficial effect on atherogenesis.
Methods and ResultsWe cloned a secreted "decoy" MSR (sMSR) that contains an extracellular portion of the human MSR type AI and constructed an adenoviral vector that directs high-level expression of sMSR in macrophages under the control of the human CD68 promoter. Expression of the sMSR protein inhibited the degradation of 125I-labeled acetylated LDL and oxidized LDL by murine macrophages up to 90%. sMSRs also reduced acetylated LDL degradation in MSR knockout mouse peritoneal macrophages by 60% to 80%, which suggests that the decoy construct can compete for the uptake mediated via other related scavenger receptors. In addition, sMSRs inhibited foam-cell formation in murine macrophages in the presence of cytochalasin D. The mechanism of inhibition is through ligand binding to the sMSRs, which prevents the ligand binding to MSRs on cell membranes.
ConclusionsThe demonstration that recombinant adenovirusmediated gene transfer of decoy sMSRs can block foam-cell formation suggests a possible new strategy for gene therapy of atherosclerosis and for the treatment of lipid accumulation after arterial manipulations.
Key Words: viruses genes receptors lipoproteins cells
This article has been cited by other articles:
![]() |
A.-L. Levonen, E. Vahakangas, J. K. Koponen, and S. Yla-Herttuala Antioxidant Gene Therapy for Cardiovascular Disease: Current Status and Future Perspectives Circulation, April 22, 2008; 117(16): 2142 - 2150. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Turunen, J. Jalkanen, T. Heikura, H. Puhakka, J. Karppi, K. Nyyssonen, and S. Yla-Herttuala Adenovirus-mediated gene transfer of Lp-PLA2 reduces LDL degradation and foam cell formation in vitro J. Lipid Res., September 1, 2004; 45(9): 1633 - 1639. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. T. Tuomisto, A. Korkeela, J. Rutanen, H. Viita, J. H. Brasen, M. S. Riekkinen, T. T. Rissanen, K. Karkola, Z. Kiraly, K. Kolble, et al. Gene Expression in Macrophage-Rich Inflammatory Cell Infiltrates in Human Atherosclerotic Lesions as Studied by Laser Microdissection and DNA Array: Overexpression of HMG-CoA Reductase, Colony Stimulating Factor Receptors, CD11A/CD18 Integrins, and Interleukin Receptors Arterioscler. Thromb. Vasc. Biol., December 1, 2003; 23(12): 2235 - 2240. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Li, V. Williams, L. Liu, H. Chen, T. Sawamura, T. Antakli, and J. L. Mehta LOX-1 inhibition in myocardial ischemia-reperfusion injury: modulation of MMP-1 and inflammation Am J Physiol Heart Circ Physiol, November 1, 2002; 283(5): H1795 - H1801. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Burke, S. Sumner, N. Maitland, and C. E. Lewis Macrophages in gene therapy: cellular delivery vehicles and in vivo targets J. Leukoc. Biol., September 1, 2002; 72(3): 417 - 428. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2000 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |